We are live on ! Find out more
AC

Armistice Capital Portfolio holdings

AUM $8.17B
1-Year Est. Return 68.82%
This Fund
S&P 500
This Quarter Est. Return
+25.15%
1 Year Est. Return
+68.82%
3 Year Est. Return
+79.68%
5 Year Est. Return
+64.24%
10 Year Est. Return
+259.8%
AUM
$8.17B
AUM Growth
+$2.55B
Cap. Flow
+$12.3M
Cap. Flow %
0.15%
Top 10 Hldgs %
61.52%
Holding
432
New
171
Increased
73
Reduced
69
Closed
99

Top Buys

Rank Stock Value
1
REGN icon
Regeneron Pharmaceuticals
REGN
+$36.5M
2
SUPN icon
Supernus Pharmaceuticals
SUPN
+$36.1M
3
SNY icon
Sanofi
SNY
+$34.1M
4
CYTK icon
Cytokinetics
CYTK
+$31.4M
5
WAT icon
Waters Corp
WAT
+$25.6M

Top Sells

Rank Stock Value
1
TVTX icon
Travere Therapeutics
TVTX
+$147M
2
PTCT icon
PTC Therapeutics
PTCT
+$72.4M
3
IMVT icon
Immunovant
IMVT
+$55.7M
4
DDOG icon
Datadog
DDOG
+$31.8M
5
AVNS
Avanos Medical
AVNS
+$28M

Sector Composition

Rank Sector Weight
1 Miscellaneous 55.89%
2 Healthcare 30.09%
3 Technology 6.58%
4 Consumer Discretionary 3.42%
5 Communication Services 1.89%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
KALV
376
DELISTED
KalVista Pharmaceuticals
KALV
– –
-1,236,000
Closed -$24.9M
KEYS icon
377
Keysight
KEYS
$55.7B
– –
-14,717
Closed -$4.16M
KMB icon
378
Kimberly-Clark
KMB
$34.9B
– –
-2,310
Closed -$223K
KVUE icon
379
Kenvue
KVUE
$36B
– –
-29,604
Closed -$510K
LCTX icon
380
Lineage Cell Therapeutics
LCTX
$273M
– –
-3,182,799
Closed -$5.03M
MASI
381
DELISTED
Masimo
MASI
– –
-1,642
Closed -$292K
MCD icon
382
McDonald's
MCD
$181B
– –
-11,527
Closed -$3.58M
META icon
383
Meta Platforms (Facebook)
META
$1.57T
– –
-32,594
Closed -$18.6M
MHK icon
384
Mohawk Industries
MHK
$9.05B
– –
-3,148
Closed -$310K
MKL icon
385
Markel Group
MKL
$22.6B
– –
-145
Closed -$278K
MMSI icon
386
Merit Medical Systems
MMSI
$5.35B
– –
-4,448
Closed -$307K
MORN icon
387
Morningstar
MORN
$7.86B
– –
-1,327
Closed -$224K
MS icon
388
Morgan Stanley
MS
$342B
– –
-3,017
Closed -$497K
MTSI icon
389
MACOM Technology Solutions
MTSI
$20.5B
– –
-16,808
Closed -$3.73M
NU icon
390
Nu Holdings
NU
$74.2B
– –
-28,475
Closed -$409K
NUWE icon
391
Nuwellis
NUWE
$2.48M
– –
-6,749
Closed -$248K
NVST icon
392
Envista
NVST
$4.38B
– –
-264,008
Closed -$6.7M
ONTO icon
393
Onto Innovation
ONTO
$13.2B
– –
-13,921
Closed -$2.85M
OTIS icon
394
Otis Worldwide
OTIS
$27.1B
– –
-3,535
Closed -$272K
OTLK icon
395
Outlook Therapeutics
OTLK
$162M
– –
-4,168,000
Closed -$858K
PDSB icon
396
PDS Biotechnology
PDSB
$12.3M
– –
-173,605
Closed -$105K
PENN icon
397
CALL
PENN Entertainment
PENN
$2.29B
– –
-900,000
Closed -$13.5M
PFSI icon
398
PennyMac Financial
PFSI
$3.81B
– –
-2,306
Closed -$202K
PRTA icon
399
Prothena Corp
PRTA
$504M
– –
-439,411
Closed -$4.27M
PTLO icon
400
Portillo's
PTLO
$321M
– –
-16,719
Closed -$88.4K
14 15
16
17 18

Similar funds

MWM
Mission Wealth Management Santa Barbara, California $8.18B AUM 28.28% 1-Year Est. Return
BP
Ballentine Partners Waltham, Massachusetts $8.18B AUM 27.59% 1-Year Est. Return
FWCM
Ferguson Wellman Capital Management Portland, Oregon $8.19B AUM 30.56% 1-Year Est. Return
SC
Saturna Capital Bellingham, Washington $8.19B AUM 42.01% 1-Year Est. Return
SFM
Soros Fund Management New York $8.14B AUM 35.85% 1-Year Est. Return
EHC
Everett Harris & Co Los Angeles, California $8.14B AUM 14.79% 1-Year Est. Return
BIM
Bridges Investment Management Omaha, Nebraska $8.22B AUM 21.38% 1-Year Est. Return
WF
Welch & Forbes Boston, Massachusetts $8.23B AUM 17.62% 1-Year Est. Return

Armistice Capital's Q2 2026 Portfolio in Review

As of Q2 2026, Armistice Capital held 432 positions worth $8.17B, up 45% from $5.62B the previous quarter. Its ten largest holdings account for 62% of the portfolio.

Armistice Capital's Q2 2026 filing shows 171 new, 73 increased, 69 reduced and 99 closed positions. Its largest new stake was Waters Corp: 75,004 shares worth $28.1M. The largest sale was Travere Therapeutics, an estimated $147M.

By sector, the portfolio is most concentrated in Miscellaneous at 56% of assets, up from 46% a quarter earlier, followed by Healthcare and Technology.

  • Armistice Capital's largest Q2 2026 buy was Waters Corp: 75,004 shares worth $28.1M.
  • Armistice Capital added most to Regeneron Pharmaceuticals in Q2 2026, an estimated $36.5M increase.
  • Armistice Capital's biggest Q2 2026 reduction was Travere Therapeutics, cutting an estimated $147M.
  • Armistice Capital fully exited Avanos Medical in Q2 2026, selling an estimated $28M.
  • Armistice Capital's ten largest holdings make up 62% of its $8.17B portfolio in Q2 2026.
  • Armistice Capital opened 171 new positions and closed 99 in Q2 2026.
  • Armistice Capital's portfolio value rose 45% quarter-over-quarter to $8.17B.

Based on Armistice Capital's 13F filing for Q2 2026, filed 14 Aug 2026.